Clinical aspects of acute intermittent porphyria in northern Sweden: A population-based study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 5, 2009, Pages 612-618

  Bylesjö, Ingemar ^a   Wikberg, Agneta ^a   Andersson, Christer ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Acute intermittent porphyria; Associated disease; Precipitating factor; Prognosis; Signs and symptoms

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOLEVULINIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; BILE ACID; CALCIUM ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PORPHOBILINOGEN; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; TRIACYLGLYCEROL;

ACUTE INTERMITTENT PORPHYRIA; ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE DURATION; DRUG SAFETY; DRUG USE; FEMALE; GENE MUTATION; HETEROZYGOTE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MORBIDITY; MYALGIA; ONSET AGE; PENSION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SWEDEN; URINE LEVEL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HETEROZYGOTE; HUMANS; INSURANCE, DISABILITY; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; PORPHYRIA, ACUTE INTERMITTENT; SICK LEAVE; SMOKING; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 70249137583     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510902935979     Document Type: Article

References (35)

1. Anderson K, Sassa S, Bishop D, Desnick R. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill 2001;2991-3080.
2. Thunell S, Floderus Y, Henrichson A, Harper P. Porphyria in Sweden. Pysiolo Res. 2006;55(Suppl. 2):S109-118 .
3. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest. 2000;60:643-648
4. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 2002;48:1891-1900
5. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine. 1992;71:1-13.
6. Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003;254:176-183
7. Elder GH, Hift RJ, Meissner PN. The acute porphyrias.Lancet. 1997;349:1613-1617
8. Waldenström J. The porphyrias as inborn errors of metabolism. Am J Med. 1957;22:758-773
9. Laiwah AA, Mactier R, McColl KE, Moore MR, Goldberg A. Early-onset chronic renal failure as a complication of acute intermittent porphyria. Q J Med. 1983;52:92-98
10. Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med. 1994;236:169-175
11. Church SE, McColl KEL, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant. 1992;7:986-990
12. Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y,Deybach JC. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000;32:933-939
13. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med. 1996;240:195-201. (Pubitemid 26356041)
14. Bengtsson NO, Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer. 1986;54:115-117
15. Gubler JG, Bargetzi MJ, Meyer UA. Primary liver carcinoma in two sisters with acute intermittent porphyria [letter]. Am J Med. 1990;89:540-541
16. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand. 1984;215:271-274
17. Mauzerall D, Granick S. The occurrence and determination of delta-aminolevulinic acid and porpho-bilinogen in urine. J Biol Chem. 1956;219:435-446
18. Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet. 2002;62:288-297
19. Zanchetti A, Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Omae T, Reid J, Safar M. The 1993 guidelines for the management of mild hypertension: Memorandum from a WHO/ISH meeting. Blood Pressure. 1993;2:86-100. (Pubitemid 23283623)
20. WHO Study Group. Diabetes Mellitus. Technical Report Series 727. Geneva: World Health Organization, 1985:9-17.
21. Anderson KE. LHRH analogues for hormonal manipulation in acute intermittent porphyria. Semin Hematol. 1989;26:10-15
22. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine. 2005;84:48-60.
23. Hultdin J, Schmauch A, Wikberg A, Dahlquist G, Andersson C. Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr. 2003;92:562-568
24. Kaplan PW, Lewis DV. Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. J Child Neurol. 1986;1:38-45.
25. Waldenström J. Studien über Porphyrie. Acta Med Scand. 1937;92(Suppl. 82):1-254.
26. Goldberg A. Acute intermittent porphyria: a study of 50 cases. Q J Med. 1959;110:183-209.
27. Zimmerman T, McMillin J, Watson C. Onset of manifestations of hepatic porphyria in relation to the infl uence of female sex hormones. Arch Intern Med. 1966;118:229-240
28. Mustajoki P, Koskelo P. Hereditary hepatic porphy-rias in Finland. Acta Med Scand. 1976;200:171-178
29. Lip GY, McColl KE, J, Goldberg A, Moore MR. Smoking and recurrent attacks of acute intermittent porphyria. Br Med J. 1991;302:507.
30. Mustajoki P, NordmannY.Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 1993;153:2004-2008
31. Stein J, Tschudy D. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine. 1970;49:1-16.
32. Allard SA, Charles PJ, Herrick AL, McColl KE, Scott JT. Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermittent porphyria. Ann Rheum Dis. 1990;49:246-248
33. Allard SA, Scott JT. Systemic lupus erythematosus and acute intermittent porphyria. Br J Rheumatol. 1989;28:254-256
34. Rosemarin JI, Nigro EJ, Levere RD, Mascarenhas BR. Systemic lupus erythematosus and acute intermittent porphyria: coincidence or association ? Arthritis Rheum. 1982;25:1134-1137
35. Pischik E. Neurological manifestations of acute intermittent porphyria in north western Russia [Medical dissertation]. Helsinki: University of Helsinki; 2006.